Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Are the Long-Term Growth Opportunities and Market Size Outlook for the Respiratory Biologics Market?
The respiratory biologics market size has grown rapidly in recent years. It will grow from $6.38 billion in 2024 to $7.41 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing prevalence of respiratory diseases, rising adoption of personalized medicine, growing healthcare expenditure globally, increasing awareness and diagnosis rates of respiratory conditions, and an expanding geriatric population with respiratory disorders.
The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $13.51 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to the rising prevalence of asthma and COPD, increasing adoption of biologic therapies, increasing R&D spending, increasing demand for non-invasive drug delivery, and expansion of reimbursement policies. Major trends in the forecast period include adoption of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery methods, regulatory approvals, strategic collaborations and acquisitions among key players, and integration of artificial intelligence in drug discovery and development.
Claim your free report sample now:
What Are the Key Drivers of the Respiratory Biologics Market?
The rise in air pollution is expected to propel the growth of the respiratory biologics market going forward. Air pollution refers to the presence of harmful substances such as gases, particulate matter, and biological molecules in the Earth's atmosphere, which can negatively impact human health and the environment. Air pollution is increasing due to rising industrialization and urbanization, leading to higher emissions of pollutants from factories, vehicles, and construction activities. Respiratory biologics help combat the health effects of air pollution by providing targeted therapies that reduce inflammation and improve lung function in individuals exposed to airborne pollutants. For instance, in January 2025, according to the Environmental Protection Agency, a US-based government agency, the United States released over 66 million tons of pollutants into the atmosphere in 2023. Moreover, in September 2022, according to the United Nations Environment Programme, a Kenya-based environmental authority, air pollution results in 7 million early deaths annually, and 99% of the world's population breathe dirty air. Therefore, the rise in air pollution is driving the growth of the respiratory biologics market.
How Is the Respiratory Biologics Market Divided by Type and Application?
The respiratory biologics market covered in this report is segmented –
1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome
2) By Route Of Administration: Intravenous, Subcuteneous
3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies
Subsegments:
1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma
2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps
3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES
How Are Innovation and Technology Shaping the Future Trends of the Respiratory Biologics Market?
Major companies operating in the respiratory biologics market are focusing on developing innovative biologic therapies, such as targeted immune therapies for chronic respiratory diseases, to provide targeted treatments that reduce inflammation and improve lung function. Targeted immune therapies for chronic respiratory diseases are treatments that help control the body’s defense system to reduce swelling and breathing problems in long-term lung conditions. For instance, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who had an eosinophilic phenotype. This approval marked a significant milestone, as Dupixent became the first biologic medicine authorized in the US for treating this specific group of COPD patients.
What Are the Top Companies to Watch in the Respiratory Biologics Market?
Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.
Get the full respiratory biologics market report here:
How Does Respiratory Biologics Market Growth Vary Across Major Regions?
North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment